Horizon Pharma, Par Pharmaceutical autoimmune, gastrointestinal news

Horizon filed suit in the U.S. District Court for the District of Delaware alleging an ANDA submission from Par for a generic version of Horizon's Duexis ibuprofen/famotidine infringes U.S. Patent No. 8,067,033. The patent, which expires July 18, 2026, covers the pharmaceutical composition of famotidine and ibuprofen. Horizon said it filed the suit within 45 days of receipt of Par's Paragraph IV notification that the generic would not infringe the patent or that the patent is invalid or unenforceable. Horizon is seeking to prevent commercialization of the generic until after the latest expiration or exclusivity date of the patent, plus monetary damages should Par breach the injunction. Par declined to comment. ...